Funding for this research was provided by:
Received: 18 September 2020
Revised: 9 December 2020
Accepted: 10 December 2020
First Online: 29 December 2020
Compliance with ethical standards
: CK, KF, ST, MH, FD, and MD have nothing to disclose. FAW reports personal fees from Bayer, Pfizer-BMS, Portola, and Boehringer Ingelheim outside of this study. TL consults for Stryker Neurovascular GmbH and has received speaker honoraria by Pfizer, Covidien, Phenox, and Microvention outside this study. LK has received funding for travel or speaker honoraria from Bayer Vital, Boehringer Ingelheim, Bristol-Meyer-Squibb, Daiichi Sankyo, and Pfizer outside of this study.
: The study was centrally approved by the Ethics Committee of the Ludwig Maximilians University LMU, Munich (689-15), as the leading ethics committee. Further approval was obtained from local ethics committees or institutional review boards according to local regulations. The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments.
: An informed consent was not mandatory in accordance with the institutional review board approval, because no study-specific procedures were performed and data sampling from patients undergoing ET is already mandated by national law for quality control reasons.